Navigation Links
Oncology is the Most Active Therapeutic Area for Phase II/III R&D
Date:11/21/2013

BURLINGTON, Mass., Nov. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while metabolic drugs account for one-quarter of drugs recently filed for approval or approved, oncology continues to be the most active therapeutic area for Phase II and III research and development (R&D). Among the top 25 biopharmaceutical companies, oncology is the focus for 30 percent of Phase II drugs and 22 percent of Phase III drugs. According to Decision Resources' Strategic Insights report entitled R&D Trends: Will Pharma's Investment Deliver?, other active therapeutic areas of R&D include obesity drugs, anti-diabetics, anti-infectives, central nervous system drugs, musculoskeletal/pain drugs and respiratory drugs.

The analysis also reveals that despite enduring multiple failures in 2011 and 2012 with drugs in Phase III development, Novartis is poised to benefit from a rich Phase III pipeline. Decision Resources expects Novartis will replace Pfizer as the top global biopharmaceutical company in 2015.

"To maximize R&D investments, biopharmaceutical companies must continue to address Phase II and III attrition and identify better prospects early on," said Decision Resources Group Senior Vice President Kate Hohenberg. "As more than half of the costs associated with new drugs are accrued from Phase II on, this could lead to significant cost savings."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company. <
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013s Top Oncology Projects to Watch
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
4. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
5. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
7. Oncology Therapeutics Market in India to 2018 Report
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
10. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... (PRWEB) November 25, 2014 Miles Holder, ... joined the Graphel Carbon Products team as Sales/Marketing Manager. ... marketing, and customer service for the graphite industry. , ... to our team,” stated Dave Trinkley, VP of Market ... wide range of experience in the graphite industry, along ...
(Date:11/26/2014)... TOKYO , 25 novembre 2014 Theravalues ... Super sur le marché européen au salon Hi ... Amsterdam ). Curcumine la ... une technologie amorphe (non-cristalline) à des ingrédients approuvés ... est un pigment jaune présent dans la racine ...
(Date:11/24/2014)... BUENA, N.J. , Nov. 24, 2014  IGI ... Jersey based specialty generic pharmaceutical company, today ... application (ANDA) to the U.S. Food and Drug Administration ... submissions in 2014 to seven, with eighteen submissions now ... Grenfell-Gardner , President and CEO of the Company, commented, ...
(Date:11/24/2014)... --   First published articles ... Elsevier , a world-leading provider of scientific, technical and ... launch of the latest title in the Current Opinion ... Science . Current Opinion ... platform to keep up-to-date with the expanding volume of information ...
Breaking Biology Technology:Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3IGI Laboratories, Inc. Announces ANDA Submission 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 2Elsevier Announces Launch of New Journal: Current Opinion in Food Science 3
... /Xinhua-PRNewswire-FirstCall/ -- China,Biologic Products, Inc. (OTC Bulletin ... of the leading plasma-based pharmaceutical companies in ... guidance following,the recently announced acquisitions which will ... of plasma based products in China., ...
... AMES, Iowa, Oct. 16 Advanced Analytical Technologies,Inc. (AATI), ... production space,adding an additional 1200 ft2 of space to ... company occupies in Building 4 on the,ISU Research Park ... company will continue to occupy space in 2 building ...
... Radiation Therapy Trials to US ... Patients for First Time, HOUSTON, Oct. 16 The ... they have entered into a,collaboration to increase patient access to ... setting., The collaboration means patients receiving cancer care at ...
Cached Biology Technology:China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million 2China Biologic Products Provides Preliminary Guidance for 2009 of Revenues of $90 to $100 Million and Net Income of $18 to 22 Million 3Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space 2Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 2Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 3Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 4Radiation Therapy Oncology Group and US Oncology Enter Collaboration to Increase Patient Access to National Clinical Trials 5
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
(Date:11/3/2014)... A University of Colorado Cancer Center study ... Academy of Sciences describes the activity of a ... Interleukin 37 or IL-37. It has been known to ... in the adaptive immune system: IL-37 inhibits the ability ... antigens. , "Knowing this mechanism that underlies IL-37,s effect ...
(Date:11/3/2014)... birth weight and preterm birth are linked to increased ... published in the American College of Rheumatology (ACR) journal, ... birth weight and pre-term babies were not at greater ... , According to the ACR, 27 million Americans ... OA. Symptoms of OA range from mild to severe ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2
... A University of Oklahoma-led study has demonstrated that ancient ... The microbiomes from ancient people have broad reaching implications ... what good bacteria might have been lost as a ... aseptic practices. Cecil M. Lewis Jr., professor of ...
... cell is like a small city, with factoriescalled organellesdedicated ... functions. A network of intercellular "highways," called microtubules, enables ... about the cell to keep this vital machinery humming. ... Proceedings of the National Academy of Sciences sheds ...
... researchers from across the Asia-Pacific gathered today for the ... Osteoporosis Meeting, taking place at the Kuala Lumpur Convention ... Minister of Health of Malaysia, YB Datuk Rosnah bt. ... than 60 nations. His Excellency Tun Dato, Seri Utama ...
Cached Biology News:OU study suggests the bacterial ecology that lives on humans has changed in the last 100 years 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 2Study sheds light on how cells transport materials along crowded intercellular 'highways' 3IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management 2IOF Asia-Pacific Meeting presents new research and advances in osteoporosis management 3
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... Amplification Kit, 100 reactions. Prepare circular ... 4-6 h.Generate microgram quantities of template ... material.Use amplified DNA directly for cycle ... or M13 liquid cultures, colonies, plaques, ...
... Microplate Rack inserts fit ... Rack, and allow you to ... capacity, shake deepwell format plates ... many plates from the shaker ...
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: